Kosh Agarwal
Consultant Hepatologist and Transplant Physician, Institute of Liver Studies, King’s College Hospital
Kosh Agarwal is a Consultant Hepatologist and Transplant Physician at the Institute of Liver Studies at King’s College Hospital in London, UK. He is one of five transplant hepatologists, delivering the largest liver transplant program in Europe. Dr Agarwal is also Lead for the Viral Hepatitis Service, the largest treatment centre for viral hepatitis in the UK.
In 1991 Dr Agarwal graduated from Newcastle University, UK and his postgraduate training was undertaken in Newcastle with the majority of his clinical and research training at the Regional Liver and Transplant Unit. He also spent a year at the Division of Liver Diseases, Mount Sinai, New York, USA. Dr Agarwal is an investigator for several ongoing studies evaluating the safety and efficacy of various antiviral treatment regimens for chronic hepatitis B and C. He is a member of EASL, AASLD, the British Association for the Study of the Liver, and the International Liver Transplantation Society.
1. Foster GR, Pianko S, Brainard DM, Cooper C, Brown A, Forton D, Nahass RG, George J, Barnes E, Brainard D, Massetto B, Lin M, Han B, McHutchison JG. Subramanian GM, Agarwal K; BOSON Study Group. Sofosbuvir Plus Ribavirin With or Without Peginterferon-alfa in Patients With HCV Genotype 3 and Treatment-Experienced Cirrhotic Patients with HCV Genotype 2 (BOSON): An Open-Label, Randomised, Phase 3 Trial. Gastroenterology 2015: 149(6): 1462-70
2. Feld JJ, Jacobson I, Hézode C, Asselah T, Ruane PJ, Gruener N, Abergel A, Mangia A, Lai CL, Chan HL, Mazzotta F, Moreno C, Yoshida E, Shafran SD, Towner WJ, Tran TT, McNally J, Osinusi A, Svarovskaia E, Zhu Y, Brainard DM, McHutchison JG, Agarwal K, Zeuzem S; ASTRAL-1 Investigators. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med 2015: 373(27): 2599-607
3. Foster GR, Afdhal N, Roberts SK, Bräu N, Gane EJ, Pianko S, Lawitz E, Thompson A, Shiffman ML, Cooper C, Towner WJ, Conway B, Ruane P, Bourlière M, Asselah T, Berg T, Zeuzem S, Rosenberg W, Agarwal K, Stedman CA, Mo H, Dvory-Sobol H, Han L, Wang J, McNally J, Osinusi A, Brainard DM, McHutchison JG, Mazzotta F, Tran TT, Gordon SC, Patel K, Reau N, Mangia A, Sulkowski M; ASTRAL-2 Investigators; ASTRAL-3 Investigators. Sofosbuvir and Velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med 2015: 373(27): 2608-17
4. Foster GR, William L Irving WL, Cheung MCM, Walker AJ, Hudson BE, Verma S, McLauchlan J, Mutiner DJ, Brown A, Gelson WTH, MacDonald DC, Agarwal K. Cohort study of the impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol accepted
